← Leaderboards
Alan Keith Meeker
Johns Hopkins University
$5,318,574
Attributed
$6,984,438
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,984,438 · 5
By mechanism
R01$5,016,113 · 3
P30$1,968,325 · 2
Top collaborators
- Elizabeth A. Platz5 shared
- Christopher M Heaphy3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Constance A Griffin$6,423,088
- Angelo Michael De Marzo$8,441,808
- Martin G Pomper$38,517,075
- Christopher B Umbricht$5,202,537
- Elizabeth A. Platz$18,230,919
Others in their field
Top investigators on “Tissues”
- David Heimbrook · Leidos Biomedical Research, Inc.$346,311,904
- Lawrence Corey · Fred Hutchinson Cancer Center$230,011,824
- Larry Arthur$159,140,370
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Judith S. Currier · University Of California Los Angeles$138,805,403
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$138,805,403
Research focus
TissuesGrowthResearch PersonnelImmunofluorescence ImmunologicMalignant NeoplasmsStainsImage AnalysisCellsCancer CellImageDesignCessation Of LifeBiological MarkersTissue MicroarrayQuantitative ImagingBaseTelomerePerformanceTelomere ShorteningEnzymesProteinsPrognosisCohortEvent
Grant awards (20)
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy$534,909
R01 · FY2025 · CA · contact PI
Oncology Tissue and Imaging Services$299,086
P30 · FY2025 · CA · contact PI
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy$262,383
R01 · FY2025 · CA
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy$505,583
R01 · FY2024 · CA · contact PI
Oncology Tissue and Imaging Services$359,913
P30 · FY2024 · CA · contact PI
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy$136,789
R01 · FY2024 · CA
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy$622,964
R01 · FY2023 · CA · contact PI
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy$411,778
R01 · FY2023 · CA
Oncology Tissue and Imaging Services$359,913
P30 · FY2023 · CA · contact PI
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy$411,778
R01 · FY2022 · CA
Oncology Tissue and Imaging Services$359,913
P30 · FY2022 · CA · contact PI
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy$445,544
R01 · FY2021 · CA
Oncology Tissue$196,500
P30 · FY2021 · CA · contact PI
Oncology Tissue$196,500
P30 · FY2020 · CA · contact PI
Oncology Tissue$196,500
P30 · FY2019 · CA · contact PI
Determining the Roles of ATRX and DAXX Abnormalities in Cancer Telomere Biology$335,820
R01 · FY2017 · CA · contact PI
Determining the Roles of ATRX and DAXX Abnormalities in Cancer Telomere Biology$335,820
R01 · FY2016 · CA · contact PI
Determining the Roles of ATRX and DAXX Abnormalities in Cancer Telomere Biology$335,820
R01 · FY2015 · CA · contact PI
Determining the Roles of ATRX and DAXX Abnormalities in Cancer Telomere Biology$330,263
R01 · FY2014 · CA · contact PI
Determining the Roles of ATRX and DAXX Abnormalities in Cancer Telomere Biology$346,662
R01 · FY2013 · CA · contact PI